U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT06883539) titled 'A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.' on March 06.
Brief Summary: A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with advanced solid tumor.
Patients with advanced solid tumors that are refractory to currently available therapies or for whom no effective treatment is available will be selected.
The main questions it aims to answer are:
1. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of LXP1788 ...